PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines

I. Nakachi, B. A. Helfrich, M. A. Spillman, E. A. Mickler, C. J. Olson, J. L. Rice, C. D. Coldren, L. E. Heasley, M. W. Geraci, R. S. Stearman

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Src kinase is recognized as a key target for molecular cancer therapy. However, methods to efficiently select patients responsive to Src inhibitors are lacking. We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib to identify predictive markers of drug sensitivity using gene microarrays. Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression. PTTG1 expression was correlated with proliferation, cell division, and mitosis in ovarian cancer tissues data sets. In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels. Downregulating PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines. Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.

Original languageEnglish (US)
JournalClinical and Translational Science
DOIs
StateAccepted/In press - 2016

Fingerprint

Pituitary Neoplasms
Oncogenes
Ovarian Neoplasms
Tumors
Genes
Cells
Cell Line
src-Family Kinases
Biomarkers
Securin
Fibroblast Growth Factor 2
Mitosis
Cell Division
Cell proliferation
Microarrays
saracatinib
Down-Regulation
Proteins
Gene Expression
Messenger RNA

ASJC Scopus subject areas

  • Neuroscience(all)
  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Nakachi, I., Helfrich, B. A., Spillman, M. A., Mickler, E. A., Olson, C. J., Rice, J. L., ... Stearman, R. S. (Accepted/In press). PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. Clinical and Translational Science. https://doi.org/10.1111/cts.12413

PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. / Nakachi, I.; Helfrich, B. A.; Spillman, M. A.; Mickler, E. A.; Olson, C. J.; Rice, J. L.; Coldren, C. D.; Heasley, L. E.; Geraci, M. W.; Stearman, R. S.

In: Clinical and Translational Science, 2016.

Research output: Contribution to journalArticle

Nakachi, I, Helfrich, BA, Spillman, MA, Mickler, EA, Olson, CJ, Rice, JL, Coldren, CD, Heasley, LE, Geraci, MW & Stearman, RS 2016, 'PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines', Clinical and Translational Science. https://doi.org/10.1111/cts.12413
Nakachi, I. ; Helfrich, B. A. ; Spillman, M. A. ; Mickler, E. A. ; Olson, C. J. ; Rice, J. L. ; Coldren, C. D. ; Heasley, L. E. ; Geraci, M. W. ; Stearman, R. S. / PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines. In: Clinical and Translational Science. 2016.
@article{21050e74c7dd4a26bff7197b44421897,
title = "PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines",
abstract = "Src kinase is recognized as a key target for molecular cancer therapy. However, methods to efficiently select patients responsive to Src inhibitors are lacking. We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib to identify predictive markers of drug sensitivity using gene microarrays. Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression. PTTG1 expression was correlated with proliferation, cell division, and mitosis in ovarian cancer tissues data sets. In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels. Downregulating PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines. Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.",
author = "I. Nakachi and Helfrich, {B. A.} and Spillman, {M. A.} and Mickler, {E. A.} and Olson, {C. J.} and Rice, {J. L.} and Coldren, {C. D.} and Heasley, {L. E.} and Geraci, {M. W.} and Stearman, {R. S.}",
year = "2016",
doi = "10.1111/cts.12413",
language = "English (US)",
journal = "Clinical and Translational Science",
issn = "1752-8054",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - PTTG1 Levels Are Predictive of Saracatinib Sensitivity in Ovarian Cancer Cell Lines

AU - Nakachi, I.

AU - Helfrich, B. A.

AU - Spillman, M. A.

AU - Mickler, E. A.

AU - Olson, C. J.

AU - Rice, J. L.

AU - Coldren, C. D.

AU - Heasley, L. E.

AU - Geraci, M. W.

AU - Stearman, R. S.

PY - 2016

Y1 - 2016

N2 - Src kinase is recognized as a key target for molecular cancer therapy. However, methods to efficiently select patients responsive to Src inhibitors are lacking. We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib to identify predictive markers of drug sensitivity using gene microarrays. Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression. PTTG1 expression was correlated with proliferation, cell division, and mitosis in ovarian cancer tissues data sets. In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels. Downregulating PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines. Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.

AB - Src kinase is recognized as a key target for molecular cancer therapy. However, methods to efficiently select patients responsive to Src inhibitors are lacking. We explored the sensitivity of ovarian cancer cell lines to the Src kinase inhibitor saracatinib to identify predictive markers of drug sensitivity using gene microarrays. Pituitary tumor transforming gene 1 (PTTG1) was selected as a potential biomarker as mRNA levels were correlated with saracatinib resistance, as well as higher PTTG1 protein expression. PTTG1 expression was correlated with proliferation, cell division, and mitosis in ovarian cancer tissues data sets. In sensitive cell lines, saracatinib treatment decreased PTTG1 and fibroblast growth factor 2 (FGF2) protein levels. Downregulating PTTG1 by siRNAs increased saracatinib sensitivity in two resistant cell lines. Our results indicate PTTG1 may be a valuable biomarker in ovarian cancer to predict sensitivity to saracatinib, and could form the basis of a targeted prospective saracatinib trial for ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=84991766077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84991766077&partnerID=8YFLogxK

U2 - 10.1111/cts.12413

DO - 10.1111/cts.12413

M3 - Article

C2 - 27766744

AN - SCOPUS:84991766077

JO - Clinical and Translational Science

JF - Clinical and Translational Science

SN - 1752-8054

ER -